Biogen Idec Suggests PML Risk Manageable For Tecfidera, After Reporting First Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Deadly brain disease casts shadow over a quarter in which the company reports progress on new launches, including hemophilia, but PML occurred in only one in 100,000 treated and experience suggests risk can be managed.
You may also be interested in...
As Majority Of U.S. Patients Tested For JCV, Tysabri Sales Rise, Elan Says
The Irish company is still dealing with the after-effects of splitting apart its business in 2011, including its search for a new CEO. Meanwhile, Elan’s lead revenue driver, Tysabri continues to grow.
Tysabri’s PML Risk Quantified In Revised Label; Can Added Certainty Add Scripts?
Multiple sclerosis and Crohn’s disease patients with anti-JC virus antibodies who have previously taken other immunosuppressants have a 1.1% risk of developing the deadly neurological condition after taking Biogen Idec /Elan’s Tysabri for more than two years.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.